Michael Weller

Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial.

CAMTA1 is a novel tumour suppressor regulated by miR-9/9* in glioblastoma stem cells.

Intravenous and oral levetiracetam in patients with a suspected primary brain tumor and symptomatic seizures undergoing neurosurgery: the HELLO trial.

2-Hydroxyglutarate concentration in serum from patients with gliomas does not correlate with IDH1/2 mutation status or tumor size.

Geriatric neuro-oncology: from mythology to biology.

An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor.

Clinical trials in neuro-oncology: one step forward, two steps back?

Costimulatory protein 4IgB7H3 drives the malignant phenotype of glioblastoma by mediating immune escape and invasiveness.

Predictive impact of MGMT promoter methylation in glioblastoma of the elderly.

Non-invasive monitoring of immunization progress in mice via IgG from feces.

Immunology of brain tumors.

Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial.

Individualized targeted therapy for glioblastoma: fact or fiction?

Extremely sensitive and selective antibodies against the explosive 2,4,6-trinitrotoluene by rational design of a structurally optimized hapten.

Monitoring the glioma tropism of bone marrow-derived progenitor cells by 2-photon laser scanning microscopy and positron emission tomography.

Sustained efficacy of natalizumab in the treatment of relapsing-remitting multiple sclerosis independent of disease activity and disability at baseline: real-life data from a Swiss cohort.

Autoimmune myasthenia gravis after sternal fracture.

Is there a world beyond bevacizumab in targeting angiogenesis in glioblastoma?

Clinical implications of molecular neuropathology and biomarkers for malignant glioma.

Prognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma.

Antiepileptic drugs and vitamin B6 plasma levels in adult patients.

Comparative evaluation of the drug interaction screening programs MediQ and ID PHARMA CHECK in neurological inpatients.

More on the immune privilege of glioblastoma.

Phase 2 trial design in neuro-oncology revisited: a report from the RANO group.

Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells.

Pathogenesis and management of primary CNS lymphoma.

Immunoassays as high-throughput tools: monitoring spatial and temporal variations of carbamazepine, caffeine and cetirizine in surface and wastewaters.

HLA-E contributes to an immune-inhibitory phenotype of glioblastoma stem-like cells.

Optimal management of elderly patients with glioblastoma.

Progressive dopamine and hypocretin deficiencies in Parkinson's disease: is there an impact on sleep and wakefulness?

Drug-related problems and factors influencing acceptance of clinical pharmacologists` alerts in a large cohort of neurology inpatients.

Comparison of the fragmentation behavior of differentially metal-coded affinity tag (MeCAT)-labeled peptides.

MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status.

Antiangiogenic treatment for multiple CNS hemangioblastomas.

Microglia: a novel treatment target in gliomas.

CT-only planning for Gamma Knife radiosurgery in the treatment of trigeminal neuralgia: methodology and outcomes from a single institution.

Outcome of elderly patients with primary CNS lymphoma in the G-PCNSL-SG-1 trial.

Epilepsy meets cancer: when, why, and what to do about it?

Surgery for primary CNS lymphoma? Challenging a paradigm.

Epidermal growth factor receptor: a re-emerging target in glioblastoma.

Deletion of the ageing gene p66Shc reduces early stroke size following ischaemia/reperfusion brain injury.

A unifying review of bioassay-guided fractionation, effect-directed analysis and related techniques.

Prime time for molecular marker diagnostics in neuro-oncology.

Angiogenesis inhibition: quo vadis?

Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice.

Standards of care for treatment of recurrent glioblastoma--are we there yet?

Bevacizumab alone or in combination with irinotecan in recurrent WHO grade II and grade III gliomas.

Expression of integrins αvβ3 and αvβ5 and their ligands in primary and secondary central nervous system neoplasms.

The costs of disorders of the brain in Switzerland: an update from the European Brain Council Study for 2010.

Integrin control of the transforming growth factor-β pathway in glioblastoma.

Assessing the MGMT status in glioblastoma: one step forward, two steps back?

Selective, sensitive, and rapid analysis with lateral-flow assays based on antibody-gated dye-delivery systems: the example of triacetone triperoxide.

High-dose praziquantel therapy for cerebral sparganosis.

Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective.

αv-Integrin isoform expression in primary human tumors and brain metastases.

Glioma cell death induced by irradiation or alkylating agent chemotherapy is independent of the intrinsic ceramide pathway.

Refined brain tumor diagnostics and stratified therapies: the requirement for a multidisciplinary approach.

The time of maximum post-ischemic hyperperfusion indicates infarct growth following transient experimental ischemia.

Primary central nervous system tumors: pathogenesis and therapy.

Acid sphingomyelinase-ceramide system mediates effects of antidepressant drugs.

Are we ready for a randomized trial of valproic acid in newly diagnosed glioblastoma?

The cascade radical cyclisation approach to prenylated alkaloids: synthesis of stephacidin A and notoamide B.

End-of-life caregivers' perception of medical and psychological support during the final weeks of glioma patients: a questionnaire-based survey.

Angiogenesis inhibition for glioblastoma at the edge: beyond AVAGlio and RTOG 0825.

JC virus granule cell neuronopathy and GCN-IRIS under natalizumab treatment.

Molecular neuro-oncology in clinical practice: a new horizon.

ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis.

Anaplastic oligodendroglioma: a new treatment paradigm and current controversies.

Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations.

APO010, a synthetic hexameric CD95 ligand, induces death of human glioblastoma stem-like cells.

Differential expression of the tumor suppressor A-kinase anchor protein 12 in human diffuse and pilocytic astrocytomas is regulated by promoter methylation.

Immunological challenges for peptide-based immunotherapy in glioblastoma.

Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation.

Invasion patterns in brain metastases of solid cancers.

EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma.

Tumor-associated edema in brain cancer patients: pathogenesis and management.

Malignant astrocytoma in elderly patients: where do we stand?

Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system.

Immunoassays and biosensors for the detection of cyanobacterial toxins in water.

Single-institution retrospective series of gamma knife radiosurgery in the treatment of multiple sclerosis-related trigeminal neuralgia: factors that predict efficacy.

Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell-mediated glioma rejection.

The legend of cytomegalovirus and glioblastoma lives on.

Levetiracetam and pregabalin for antiepileptic monotherapy in patients with primary brain tumors. A phase II randomized study.

A disintegrin and metalloproteinases 10 and 17 modulate the immunogenicity of glioblastoma-initiating cells.

Treatment of primary CNS lymphoma.

Thymosin β 4 gene silencing decreases stemness and invasiveness in glioblastoma.

mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy.

Genetic variants of homocysteine metabolism and multiple sclerosis: a case-control study.

Neuro-oncology in 2013: improving outcome in newly diagnosed malignant glioma.

Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression.

Amyotrophic lateral sclerosis after embolization of cerebral arterioveneous malformations.

Interferon-β induces loss of spherogenicity and overcomes therapy resistance of glioblastoma stem cells.

Clinical reasoning: a 30-year-old woman with recurrent seizures and a cerebral lesion progressing over 2 decades.

Etoposide/carboplatin chemotherapy for the treatment of metastatic myxomatous cerebral aneurysms.

Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy.

Molecular characterization of long-term survivors of glioblastoma using genome- and transcriptome-wide profiling.

Genomic profiling reveals distinctive molecular relapse patterns in IDH1/2 wild-type glioblastoma.

ERGO: a pilot study of ketogenic diet in recurrent glioblastoma.

Neuropathological characteristics of progression after prolonged response to bevacizumab in multifocal hemangioblastoma.

Clinical management and outcome of histologically verified adult brainstem gliomas in Switzerland: a retrospective analysis of 21 patients.

Hypoxia enhances the antiglioma cytotoxicity of B10, a glycosylated derivative of betulinic acid.

Questions regarding the optimal use of bevacizumab in glioblastoma: a moving target.

Addition of lomustine for bevacizumab-refractory recurrent glioblastoma.

MGMT testing--the challenges for biomarker-based glioma treatment.

3-Nitropropionic acid-induced ischemia tolerance in the rat brain is mediated by reduced metabolic activity and cerebral blood flow.

The vanishing role of whole brain radiotherapy for primary central nervous system lymphoma.

Primary glioblastoma cultures: can profiling of stem cell markers predict radiotherapy sensitivity?

Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma.

Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial.

Shaping the glioma immune microenvironment through tryptophan metabolism.

EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma.

Primary central nervous system lymphoma in the elderly.

αvβ3, αvβ5 and αvβ6 integrins in brain metastases of lung cancer.

Letter to the Editor: "The role of imaging in the management of progressive glioblastoma. A systematic review and evidence-based clinical practice guideline" [J Neurooncol 2014; 118:435-460].

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.

Differential regulation of TGF-β-induced, ALK-5-mediated VEGF release by SMAD2/3 versus SMAD1/5/8 signaling in glioblastoma.

Prognostic impact of intraocular involvement in primary CNS lymphoma: experience from the G-PCNSL-SG1 trial.

Reciprocal modulation of Aβ42 aggregation by copper and homocysteine.

MicroRNA-mediated down-regulation of NKG2D ligands contributes to glioma immune escape.

How stemlike are sphere cultures from long-term cancer cell lines? Lessons from mouse glioma models.

Dynamic 18F-FET PET in suspected WHO grade II gliomas defines distinct biological subgroups with different clinical courses.

Challenges to targeting epidermal growth factor receptor in glioblastoma: escape mechanisms and combinatorial treatment strategies.

Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma.

Antiangiogenic therapy for glioblastoma: current status and future prospects.

Clinically isolated neurosarcoidosis: a recommended diagnostic path.

ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma.

Does cilengitide deserve another chance?-Authors' reply.

Differentially regulated miRNAs as prognostic biomarkers in the blood of primary CNS lymphoma patients.

Biological tumor volume in 18FET-PET before radiochemotherapy correlates with survival in GBM.

Chromosome 7 gain and DNA hypermethylation at the HOXA10 locus are associated with expression of a stem cell related HOX-signature in glioblastoma.

MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.

Adjuvant versus neoadjuvant androgen deprivation with radiotherapy for prostate cancer: does sequencing matter?

Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma.

Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma.

Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups.

Efficacy of Surgery and Further Treatment of Progressive Glioblastoma.

Prognostic impact of B-cell lymphoma 6 in primary CNS lymphoma.

Transforming growth factor-β pathway activity in glioblastoma.

[Neuro-oncology].

Malignant optic glioma - the spectrum of disease in a case series.

Program director and chief resident perspectives on the educational environment of US radiation oncology programs.

The management of lomustine overdose in malignant glioma patients.

Corticosteroid use in neuro-oncology: an update.

Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities.

Modulation of cerebral endothelial cell function by TGF-β in glioblastoma: VEGF-dependent angiogenesis versus endothelial mesenchymal transition.

Brain metastasis research: a late awakening.

Management of neoplastic meningitis.

Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology.

Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials.

Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma.

Management of diffusely infiltrating glioma in the elderly.

Immunotherapy for glioblastoma: concepts and challenges.

Interferon-β Modulates the Innate Immune Response against Glioblastoma Initiating Cells.

Development of highly sensitive and selective antibodies for the detection of the explosive pentaerythritol tetranitrate (PETN) by bioisosteric replacement.

Computer-assisted quantification of motile and invasive capabilities of cancer cells.

Gliomatosis cerebri: no evidence for a separate brain tumor entity.

Carboplatin and Etoposide in Heavily Pretreated Patients with Progressive High-Grade Glioma.

Clinical Neuropathology mini-review 6-2015: PD-L1: emerging biomarker in glioblastoma?

Neurology--the next 10 years.

Introduction.

Dedication: Andrew T. Parsa.

Immunosuppressive mechanisms in glioblastoma.

Immunotherapy response assessment in neuro-oncology: a report of the RANO working group.

Amino acid positron emission tomography to monitor chemotherapy response and predict seizure control and progression-free survival in WHO grade II gliomas.

New insights into acquired temozolomide resistance in glioblastoma?

Predicting outcome of epilepsy after meningioma resection.

Control of glioma cell migration and invasiveness by GDF-15.

Erratum to: Gliomatosis cerebri: no evidence for a separate brain tumor entity.

Prolonged-release fampridine in multiple sclerosis: Improved ambulation effected by changes in walking pattern.

Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma.

Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trial.

Therapeutic options in recurrent glioblastoma--An update.

68Gallium-DOTATATE PET in meningioma: A reliable predictor of tumor growth rate?

MicroRNA-138 promotes acquired alkylator resistance in glioblastoma by targeting the Bcl-2-interacting mediator BIM.

Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome.

Glioblastoma.

Altered intraoperative cerebrovascular reactivity in brain areas of high-grade glioma recurrence.

[Gliomas – What I Have to Know in ten Questions].

Therapy for Secondary CNS Involvement in Malignant Lymphomas: No Standard Yet!

Autocrine VEGFR1 and VEGFR2 signaling promotes survival in human glioblastoma models in vitro and in vivo.

Quality Issues of Research Antibodies.

Corticosteroids compromise survival in glioblastoma.

Pharmacotherapies for the treatment of glioblastoma - current evidence and perspectives.

Glioblastoma in the Canton of Zurich, Switzerland revisited: 2005 to 2009.

Somatostatin-receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE/-TOC uptake.

Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas.

Chemotherapy for intracranial ependymoma in adults.

Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082).

Glioma.

Gene-Tailored Treatments for Brain Disorders: Challenges and Opportunities.

Current State of Immune-Based Therapies for Glioblastoma.

Immunotherapy of Brain Cancer.

Direct contact with perivascular tumor cells enhances integrin αvβ3 signaling and migration of endothelial cells.

Limited role for transforming growth factor-β pathway activation-mediated escape from VEGF inhibition in murine glioma models.

Osteopontin in cerebrospinal fluid as diagnostic biomarker for central nervous system lymphoma.

Reply to F. Felix et al and M.F. Fay et al.

Boswellic acid activity against glioblastoma stem-like cells.

Interleukin-33 in human gliomas: Expression and prognostic significance.

Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide.

The Role of Molecular Diagnostics in the Management of Patients with Gliomas.